113 related articles for article (PubMed ID: 2019587)
1. Construction and expression of alpha 1-proteinase inhibitor mutants and the effects of these mutations on secretion of the variant inhibitors.
McCracken AA; Kruse KB; Valentine J; Roberts C; Yohannes TZ; Brown JL
J Biol Chem; 1991 Apr; 266(12):7578-82. PubMed ID: 2019587
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342.
McCracken AA; Kruse KB; Brown JL
Mol Cell Biol; 1989 Apr; 9(4):1406-14. PubMed ID: 2786139
[TBL] [Abstract][Full Text] [Related]
3. Selective protein degradation in the yeast exocytic pathway.
McCracken AA; Kruse KB
Mol Biol Cell; 1993 Jul; 4(7):729-36. PubMed ID: 8400458
[TBL] [Abstract][Full Text] [Related]
4. Effects of mutations that alter the Glu264-Lys387 salt bridge on the secretion of alpha-1-proteinase inhibitor.
Brodbeck RM; Samandari T; Brown JL
J Biol Chem; 1993 Mar; 268(9):6771-6. PubMed ID: 8454649
[TBL] [Abstract][Full Text] [Related]
5. A study of the effects of altering the sites for N-glycosylation in alpha-1-proteinase inhibitor variants M and S.
Samandari T; Brown JL
Protein Sci; 1993 Sep; 2(9):1400-10. PubMed ID: 8401226
[TBL] [Abstract][Full Text] [Related]
6. Secretion of alpha 2-plasmin inhibitor is impaired by amino acid deletion in a small region of the molecule.
Toyota S; Hirosawa S; Aoki N
J Biochem; 1994 Feb; 115(2):293-7. PubMed ID: 7911462
[TBL] [Abstract][Full Text] [Related]
7. Secretion of alpha-1-proteinase inhibitor requires an almost full length molecule.
Brodbeck RM; Brown JL
J Biol Chem; 1992 Jan; 267(1):294-7. PubMed ID: 1730596
[TBL] [Abstract][Full Text] [Related]
8. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation.
Brantly M; Courtney M; Crystal RG
Science; 1988 Dec; 242(4886):1700-2. PubMed ID: 2904702
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the properties of rare variants of alpha1-proteinase inhibitor expressed in COS-1 cells and assessment of their potential as risk factors in human disease.
Ray S; Mickleborough TD; Brown JL
Biochim Biophys Acta; 2005 Jun; 1740(3):390-402. PubMed ID: 15949707
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the 290-342 salt bridge is not responsible for the secretory defect of the PiZ alpha 1-antitrypsin variant.
Sifers RN; Hardick CP; Woo SL
J Biol Chem; 1989 Feb; 264(5):2997-3001. PubMed ID: 2563374
[TBL] [Abstract][Full Text] [Related]
11. Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.
Matthiessen HP; Willemse J; Weber A; Turecek PL; Deiteren K; Hendriks D; Ehrlich HJ; Schwarz HP
Transfusion; 2008 Feb; 48(2):314-20. PubMed ID: 18028276
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line.
Wang Z; Hilder TL; van der Drift K; Sloan J; Wee K
Anal Biochem; 2013 Jun; 437(1):20-8. PubMed ID: 23462539
[TBL] [Abstract][Full Text] [Related]
13. Yeast mutants deficient in ER-associated degradation of the Z variant of alpha-1-protease inhibitor.
McCracken AA; Karpichev IV; Ernaga JE; Werner ED; Dillin AG; Courchesne WE
Genetics; 1996 Dec; 144(4):1355-62. PubMed ID: 8978025
[TBL] [Abstract][Full Text] [Related]
14. Cellular basis for protein C deficiency caused by a single amino acid substitution at Arg15 in the gamma-carboxyglutamic acid domain.
Tokunaga F; Tsukamoto T; Koide T
J Biochem; 1996 Aug; 120(2):360-8. PubMed ID: 8889822
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep.
Smith RM; Traber LD; Traber DL; Spragg RG
J Clin Invest; 1989 Oct; 84(4):1145-54. PubMed ID: 2794051
[TBL] [Abstract][Full Text] [Related]
17. The defective secretion of a naturally occurring alpha-1-antichymotrypsin variant with a frameshift mutation.
Tsuda M; Sei Y; Ohkubo T; Yamamura M; Kamiguchi H; Akatsuka A; Tsuda T; Tachikawa H; Yamamoto M; Shinohara Y
Eur J Biochem; 1996 Feb; 235(3):821-7. PubMed ID: 8654434
[TBL] [Abstract][Full Text] [Related]
18. Study of the roles of proline 391 and a highly conserved sequence in the carboxyl-terminal region of members of the serpin family in the secretion of alpha 1-proteinase inhibitor.
Brodbeck RM; Brown JL
J Biol Chem; 1994 Jun; 269(25):17252-6. PubMed ID: 8006033
[TBL] [Abstract][Full Text] [Related]
19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
20. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
